Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I D Davis

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Growth Factors (Chur, Switzerland)|May 9, 2000
A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancerI D Davis, D W Maher, J S Cebon, et al.
Gene Therapy|February 12, 1998
Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor modelsT Tüting, A Gambotto, J Baar, et al.
Investigational New Drugs|March 11, 2006
Phase II study of vinflunine in patients with metastatic renal cell carcinomaD Goldstein, S P Ackland, D R Bell, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?P L Blinman, I D Davis, A Martin, et al.
Urology|December 15, 2004
18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapyL Johns Putra, L Johns Putra, N Lawrentschuk, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 1, 2013
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyI N Olver, P Grimison, M Chatfield, et al.
Internal Medicine Journal|January 29, 2011
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering CommitteeS Lingaratnam, M A Slavin, B Koczwara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Prostate Cancer and Prostatic Diseases|April 19, 2017
Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control studyN P Papa, R J MacInnis, H Jayasekara, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Growth Factors (Chur, Switzerland)|May 9, 2000
A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancerI D Davis, D W Maher, J S Cebon, et al.
Gene Therapy|February 12, 1998
Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor modelsT Tüting, A Gambotto, J Baar, et al.
Investigational New Drugs|March 11, 2006
Phase II study of vinflunine in patients with metastatic renal cell carcinomaD Goldstein, S P Ackland, D R Bell, et al.
ESMO Open|November 17, 2023
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practiceP Grivas, E Grande, I D Davis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?P L Blinman, I D Davis, A Martin, et al.
Urology|December 15, 2004
18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapyL Johns Putra, L Johns Putra, N Lawrentschuk, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 1, 2013
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyI N Olver, P Grimison, M Chatfield, et al.
Internal Medicine Journal|January 29, 2011
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering CommitteeS Lingaratnam, M A Slavin, B Koczwara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Prostate Cancer and Prostatic Diseases|April 19, 2017
Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control studyN P Papa, R J MacInnis, H Jayasekara, et al.
Pageof 6